Pomerantz LLP Launches Investigation Into NovoCure Following Trial Failure
A 20% drop in NovoCure Limited’s stock price has triggered a formal investigation by Pomerantz LLP. The firm is examining potential securities fraud claims after the company’s Phase 3 TRIDENT trial failed to show a statistically significant survival benefit for patients using its Tumor Treating Fields therapy.
The clinical trial, designed to test the efficacy of initiating TTFields therapy during the initial chemoradiation phase for newly diagnosed glioblastoma, fell short of its primary endpoint. NovoCure disclosed these results on June 18, 2026, comparing the experimental Early Start Arm against the standard Maintenance Start Arm. Investors saw the company’s valuation plummet by $3.57 per share, closing at $14.28 following the announcement.
Pomerantz LLP, a firm specializing in securities and antitrust class litigation, is now soliciting contact from affected shareholders to determine if officers or directors engaged in unlawful business practices. Danielle Peyton is leading the outreach for those seeking to participate in potential legal action regarding the company’s disclosure of the trial outcomes.
Comments (0)
No comments yet. Be the first!